Healthcare Industry News: S.A.
News Release - August 23, 2016
Perrigo Announces Tentative FDA Approval For Generic Version Of Suprep(R) Oral Solution And Confirms Patent Challenge For Generic Version Of Mirvaso(R) Gel
DUBLIN, Aug. 23, 2016 -- (Healthcare Sales & Marketing Network) -- Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA") for the generic version of Suprep® (sodium sulfate/potassium sulfate/magnesium sulfate) oral solution. The drug is indicated for the treatment of cleansing of the colon in preparation for colonoscopy in adults. Annual sales for the past 12 months ending July 2016 were $178 million.Perrigo today also announced that it was sued by Galderma Laboratories, L.P. and Nestle Skin Health S.A. over the Company's Paragraph IV ANDA filing for the generic version of Mirvaso® (brimonidine) topical gel .33% which is indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older. Annual sales for the past 12 months ending July 2016 were $34 million.
Perrigo's CEO John T. Hendrickson S.A.ed, "These accomplishments demonstrate Perrigo's commitment to our customerS.A.d consumerS.A.ound the world. The team'S.A.ility to develop and bring to market high quality, value alternatives in important treatment categories is what continues to drive Perrigo's mission of providing Quality Affordable Healthcare Products® around the world."
About Perrigo
Perrigo Company plc, a top five global over-the-counter ("OTC") consumer goodS.A.d pharmaceutical company, offers patientS.A.d customers high quality productS.A. affordable prices. From its beginnings in 1887 aS.A.packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the world's largest manufacturer of OTC productS.A.d supplier of infant formulas for the store brand market. The Company iS.A.so a leading provider of generic extended topical prescription productS.A.d receives royalties from Multiple Sclerosis drug Tysabri®. Perrigo provides Quality Affordable Healthcare Products® acrosS.A.wide variety of product categorieS.A.d geographies primarily in North America, Europe, and Australia, as well as other markets, including IS.A.l, China and Latin America. Visit Perrigo online at (http://www.perrigo.com).
Forward-Looking S.A.ements
Certain S.A.ements in this press release are "forward-looking S.A.ements." These S.A.ements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertaintieS.A.d other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking S.A.ements. In some cases, forward-looking S.A.ements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking S.A.ements on its current expectations, assumptions, estimateS.A.d projections. While the Company believes these expectations, assumptions, estimateS.A.d projectionS.A.e reasonable, such forward-looking S.A.ementS.A.e only predictionS.A.d involve known and unknown riskS.A.d uncertainties, many of which are beyond the Company's control, including the timing, amount and cost of S.A.e repurchases, future impairment charges, the ability to achieve its guidance and the ability to execute and achieve the desired benefits of announced initiatives. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-KT for the six-month period ended December 31, 2015, as well as the Company's subsequent filings with the SEC, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking S.A.ements. The forward-looking S.A.ements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaimS.A.y intention or obligation to update or revise any forward-looking S.A.ements, whether aS.A.result of new information, future events or otherwise.
Source: Perrigo
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!